

PRINT: ISSN 0972-3757 ONLINE: ISSN 2456-6330

International Journal of
HUMAN GENETICS

Full text open access online (Since 2001)

©  Kamla-Raj IJHG 2024

PRINT: ISSN 0972-3757 ONLINE: ISSN 2456-6330

Int J Hum Genet, 24(2): 146-157 (2024)

DOI: 10.31901/24566322.2024/24.02.871

Over-Expressed CDCA4 Indicates Poor Clinical Efficacy as a Potential Therapeutic Target for Lung Adenocarcinoma

Shuangmin Hu*, Wenfei Zhao, Lijuan Sun and Peijie Liu

*Department of Respiratory Medicine, The Fifth Affiliated Hospital of Zhengzhou University,
Zhengzhou, Henan Province 450052, China*

KEYWORDS Bioinformatic Analysis. Biomarkers. Cell Division Cycle Associated Gene 4. Lung Adenocarcinoma. Prognosis

ABSTRACT The clinicopathological information and the gene expression data were utilised via The Cancer Genome Atlas (TCGA) databases. The results have shown that CDCA 4 was over-expressed in lung adenocarcinoma (LUAD) than those in normal or surrounding non-carcinoma profiles. The value of the receiver operating characteristic (ROC) curve revealed that CDCA4 can be a novel biomarker with better value for diagnose. Besides, CDCA4 expression levels were correlated with higher grades of clinical pathologic stage, higher age, and the residual tumour. CDCA4 expression was observably correlate with immune cell infiltration including macrophage cells, CD4 + T cells and B cells. Over-expression of CDCA4 in LUAD was related to a poor overall survival and first progression survival time. Additionally, the nomograms indicated that over-expression of CDCA4 might be a potential prognosis biomarker for LUAD.